Cronos Group, a Toronto-based marijuana company, predicts CBD customers in the United States will be the “largest contributor” to its sales over the next couple of years.
But company executives cautioned investors that it’s “too early to speculate” on how big the European market for CBD will become.
“It’s fair to estimate that the U.S. CBD market will likely be the largest contributor (to sales) over the next year or two,” Cronos CEO Michael Gorenstein said.
He said the company sees “significant opportunity” for CBD in Europe, but he cautioned against making sales projections.
European health regulators have said that CBD can’t be added to food, a decision the hemp industry in Europe is appealing.
“It’s probably too early to speculate on exactly how quickly the European market will unfold for CBD,” Gorenstein said.
“I don’t think we have the same clarity as we do for the Canadian market or the U.S.”
Cronos trades on the Nasdaq and the Toronto Stock Exchange as CRON.
For analysis and in-depth looks at the investment trends and deals driving the cannabis industry forward, sign up for our premium subscription service, Investor Intelligence.